Results 81 to 90 of about 3,001 (154)

Sodium‐based, geopolymer foamed composites reinforced with phosphate mine waste particulates and hemp/basalt fibers

Journal of the American Ceramic Society, Volume 108, Issue 12, December 2025.
Abstract This study investigated the mechanical, microstructural, and thermal properties of Na‐based geopolymer foams (GPFs) reinforced with varying amounts of two types of reinforcements: raw phosphate mine waste rock (PMWR) as a particulate filler, and natural (hemp) or synthetic (basalt) fibers.
Sanae Sbi, Andrew Stumpf, Abdelilah Aboulayt, Nawal Semlal, Jones Alami, Youssef Tamraoui, Waltraud M. Kriven   +6 more
wiley   +1 more source

Non-clinical safety and biodistribution of AS03-adjuvanted inactivated pandemic influenza vaccines

, 2015
Pandemic-influenza vaccines containing split-inactivated-virus antigen have been formulated with the immunostimulatory Adjuvant System AS03 to enhance the antigen immunogenicity and reduce antigen content per dose.
Didierlaurent, A.M., Segal, L., Martin, T., Destexhe, E., Wouters, S., Gautier, G., Kuper, F., Morelle, D., Garçon, N., Gal, J. Le   +9 more
core  

Flexibility of interval between vaccinations with AS03_A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18–60 and >60 years: a randomized trial

BMC Infectious Diseases, 2012
Background Flexibility of vaccination schedule and lower antigen content can facilitate pandemic vaccine coverage. We assessed the immune response and safety of AS03-adjuvanted A/California/7/2009 H1N1 pandemic vaccine containing half of the registered ...
Duval Xavier, Caplanusi Adrian, Laurichesse Henri, Deplanque Dominique, Loulergue Pierre, Vaman Tejaswini, Launay Odile, Gillard Paul   +7 more
doaj   +1 more source

Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination [PDF]

, 2015
An AS03-adjuvanted H5N1 influenza vaccine elicited broad and persistent immune responses with an acceptable safety profile up to 6 months following the first vaccination in children aged 3–9 years.GlaxoSmithKline Biologicals SA was the funding source,
Angels Jubert-Rosich, Carline Vanden Abeele, José-María Baldó, Garcia-Corbeira, Pilar, Garcés Sánchez, María, Díez Domingo, Javier, Philippe Moris, Teko, Maurice, Gillard, Paul, Jubert-Rosich, Angels, Josep Marès, María Garcés-Sánchez, Abeele, Carline Vanden, Pilar Garcia-Corbeira, Maurice Teko, Marés, Josep, Úbeda Sansano, María Isabel, Maria Victoria Planelles-Catarino, Paul Gillard, Moris, Philippe, Baldo Poblet, J. M., Planelles Cantarino, María Victoria, Javier Díez-Domingo, Isabel Ubeda   +23 more
core   +1 more source

Draft genome sequence of Aeromonas salmonicida subsp. achromogenes AS03, an atypical strain isolated from crucian carp (Carassius carassius) in the Republic of Korea

, 2013
We present the draft genome sequence of Aeromonas salmonicida subsp. achromogenes strain AS03, an atypical A. salmonicida strain that causes erythrodermatitis in crucian carp (Carassius carassius).
Jun, Jin Woo, Park, Se Chang, Kim, Ji Hyung, Chai, Ji Young, Han, Jee Eun, Shin, Sang Phil   +5 more
core   +2 more sources

No serological evidence of influenza A H1N1pdm09 virus infection as a contributing factor in childhood narcolepsy after Pandemrix vaccination campaign in Finland.

PLoS ONE, 2013
BackgroundNarcolepsy cataplexy syndrome, characterised by excessive daytime sleepiness and cataplexy, is strongly associated with a genetic marker, human leukocyte antigen (HLA) DQB1*06:02.
Krister Melén, Markku Partinen, Janne Tynell, Maarit Sillanpää, Sari-Leena Himanen, Outi Saarenpää-Heikkilä, Christer Hublin, Päivi Olsen, Jorma Ilonen, Hanna Nohynek, Ritva Syrjänen, Terhi Kilpi, Arja Vuorela, Turkka Kirjavainen, Outi Vaarala, Ilkka Julkunen   +15 more
doaj   +1 more source

Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials. [PDF]

, 2013
International audienceBACKGROUND: Pandemicinfluenza vaccinemanufacturing capacity and distribution agility is enhanced through the availabilityof equivalent antigen-sparing vaccines.
David W Vaughn, Schwarz, Tino F., Zalcman, Gerard, Adrian Caplanusi, Xavier Duval, Watanveerade, Veerachai, Vinod Bambure, Vaughn, David, Angkool Kerdpanich, Serge Fitoussi, Bambure, Vinod, Odile Launay, May Montellano, Duval, Xavier, Montellano, May, Wenzel, Jürgen J., Li, Ping, Gillard, Paul, Launay, Odile, Wolfgang Jilg, Vaughn, David W., Caplanusi, Adrian, Kerdpanich, Angkool, Schwarz, Tino, Veerachai Watanveerade, Anuradha Madan, Tino F Schwarz, Paul Gillard, Wenzel, Jürgen, Ping Li, Jürgen J Wenzel, Madan, Anuradha, Jilg, Wolfgang, Fitoussi, Serge, Gerard Zalcman   +34 more
core   +2 more sources

Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus Vaccine administered to adults during two randomized controlled trials [PDF]

, 2011
The influence of AS03(A), a tocopherol oil-in-water emulsion-based adjuvant system, on humoral and cell-mediated responses to A/California/7/2009 H1N1 pandemic vaccine was investigated. In two observer-blind studies, a total of 261 healthy adults aged 18
Walravens, Karl, Willekens, Julie, Cathy Maes, Roman, François, Clement, Frédéric, Dewé, Walthère, Julie Willekens, De Boever, Fien, Frédéric Clément, Walthère Dewé, Fien De Boever, François Roman, Emmanuel Hanon, Leroux-Roels, Geert, Geert Leroux-Roels, Hanon, Emmanuel, Karl Walravens, Maes, Cathy   +17 more
core   +1 more source

Humoral Response to the Influenza A H1N1/09 Monovalent AS03-Adjuvanted Vaccine in Immunocompromised Patients [PDF]

, 2017
In this observational study, safety and immunogenicity after one dose of the AS03-adjuvanted influenza H1N1/09 vaccine was overall appropriate in HIV-infected patients and solid-organ transplant recipients.
Giulieri, Stefano, Alves, Deolinda, Manuel, Oriol, Pascual, Manuel, Bart, Pierre-Alexandre, Calandra, Thierry, Venetz, Jean-Pierre, Hoschler, Katja, Ellefsen, Kim, Cavassini, Matthias   +9 more
core  

Organization of 2009/2010 influenza vaccination campaign in the Netherlands (based on [19], [29], [30].

, 2013
aFocetria is MF59-adjuvanted vaccine produced by Novartis.bPandemrix is AS03-adjuvanted vaccine produced by GSK.
Margot Tacken (424607), Maarten J. Postma (239601), Ronald P. Stolk (111251), Eelko Hak (217714), Giedre Gefenaite (424606), Irina Stirbu-Wagner (424609), Joke C. Korevaar (140394), Marc Bijl (38734), Kristin L. Nichol (252364), Jens Bos (424608), Bert Wolters (424610), Jan Wilschut (177577)   +11 more
core   +1 more source